Jonathan Hamilton, MD
Urology · Greenville, NCNPI 1609965508
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $199,444 of the $223,931 with a category attached, or 89.1%. Dendreon Pharmaceuticals LLC accounts for 85.3% of it on its own, with 35 other manufacturers making up the rest. Reporting peaked in 2023 at $57,430 and has fallen 64.9% since, to $20,149 in 2025. Among urology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 657 payments — averaging $340.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dendreon Pharmaceuticals LLC$191K
- Astellas Pharma US Inc$18K
- Myriad Genetic Laboratories, Inc.$6K
- Pfizer$2K
- Johnson & Johnson$780
- Janssen Global Services, LLC$500
- plus $5K from 30 others
Across 92 payments — averaging $5123.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$270K
- Astellas Pharma Global Development$201K
What the payments were for
- Consulting fees$3,6902%
- Speaking & faculty fees$199,44489%
- Travel & lodging$7,2163%
- Food & beverage$13,2756%
- Education$3060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dendreon Pharmaceuticals LLC | 331 | $190,906 |
| Astellas Pharma US Inc | 40 | $18,345 |
| Myriad Genetic Laboratories, Inc. | 27 | $6,485 |
| Pfizer | 32 | $2,036 |
| Johnson & Johnson(2 entities) | 39 | $780 |
| Janssen Global Services, LLC | 1 | $500 |
| Olympus America Inc. | 15 | $483 |
| Boston Scientific | 11 | $470 |
| AbbVie(2 entities) | 24 | $428 |
| Axonics, Inc. | 10 | $409 |
| Bayer | 20 | $379 |
| Merck | 20 | $375 |
| Coloplast | 6 | $357 |
| Baxter Healthcare | 2 | $251 |
| Endo Pharmaceuticals Inc. | 16 | $248 |
| Blue Earth Diagnostics | 9 | $202 |
| Endo USA, Inc. | 7 | $181 |
| Teleflex LLC | 8 | $159 |
| Procept Biorobotics Corporation | 2 | $155 |
| Urogen Pharma, Inc. | 5 | $111 |
| Sumitomo Pharma America, Inc. | 5 | $103 |
| AstraZeneca | 5 | $101 |
| Urovant Sciences Inc | 5 | $90 |
| Novartis | 3 | $66 |
| Myovant Sciences Inc. | 3 | $64 |
| Neotract Inc. | 1 | $54 |
| Palette Life Sciences, Inc. | 1 | $36 |
| Mimedx Group, Inc. | 1 | $23 |
| Progenics Pharmaceuticals, Inc. | 1 | $22 |
| LSI Solutions Inc | 1 | $20 |
| Angiodynamics, Inc. | 1 | $17 |
| Tolmar, Inc. | 1 | $16 |
| Integra Lifesciences Corporation | 1 | $16 |
| Laborie Medical Technologies Corp. | 1 | $16 |
| Amgen | 1 | $14 |
| Avadel Specialty Pharmaceuticals, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$223,931 in reported general payments places this provider in the 95th percentile of 434 urology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 110 | $1,262,016 |
| NubeqaDarolutamide | 27 | $326,344 |
| Thiola EcTiopronin | 12 | $93,509 |
| GemtesaVibegron | 71 | $51,518 |
| OrgovyxRelugolix | 20 | $48,899 |
| MyrbetriqMirabegron | 46 | $28,125 |
| Tamsulosin Hcl | 190 | $3,212 |
| Methenamine Hippurate | 32 | $2,512 |
| Solifenacin Succinate | 88 | $2,381 |
| Silodosin | 17 | $1,365 |
| Finasteride | 70 | $889 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 18 | $614 |
| Oxybutynin Chloride | 15 | $481 |
| Ciprofloxacin Hcl | 77 | $325 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 15 | $264 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $18,345 | $1,290,140156 claims |
| BayerNubeqa | $379 | $326,34427 claims |
| Sumitomo Pharma America, Inc.Gemtesa, Orgovyx | $103 | $100,41791 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 434 urology providers in North Carolina.
Other urology in Greenville
- Matthew CollinsGreenville$41K
- Robert LippittSmithfield$11.4M
- Michael KennellyCharlotte$1.3M
- John KasparRaleigh$1.1M
- Judd MoulDurham$1M
- Daniel GeorgeDurham$1M
- Scott MacdiarmidGreensboro$774K
- Glenn PremingerDurham$736K
- Michael LipkinDurham$293K
- Culley CarsonChapel Hill$275K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.